Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 472 | 66 | 404 |
| Samples | 203 | 47 | 155 |
| Peptides | 107 | 17 | 94 |
Function
MICA · MHC class I polypeptide-related sequence A
This gene encodes the highly polymorphic major histocompatability complex class I chain-related protein A. The protein product is expressed on the cell surface, although unlike canonical class I molecules it does not seem to associate with beta-2-microglobulin. It is a ligand for the NKG2-D type II integral membrane protein receptor. The protein functions as a stress-induced antigen that is broadly recognized by intestinal epithelial gamma delta T cells. Variations in this gene have been associated with susceptibility to psoriasis 1 and psoriatic arthritis, and the shedding of MICA-related antibodies and ligands is involved in the progression from monoclonal gammopathy of undetermined significance to multiple myeloma. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Jan 2014].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000449934 | A0A0G2JI23* | 273 | 107 |
| ENST00000616296 | A0A024RCL3* | 199 | 76 |
Gene Properties
Recurrent Mutations
All 107 amino-acid changes on canonical ENST00000449934 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MICA · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MICA – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Rhabdomyosarcoma | 0/33 0% | 6/171 4% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Melanoma | 3/210 1% | 20/1899 1% |
| Endometrial Carcinoma | 0/42 0% | 7/612 1% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 10/1390 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 14/1592 1% |
| Colorectal Carcinoma | 4/143 3% | 24/3239 1% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 2/810 0% |
| Biliary Tract Carcinoma | 1/54 2% | 6/950 1% |
| Neuroendocrine Tumour | 1/154 1% | 3/577 1% |
| Small Cell Lung Carcinoma | 1/9 11% | 3/752 0% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 11/2550 0% |
| Ovarian Carcinoma | 1/109 1% | 4/998 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Other Sarcomas | 2/69 3% | 1/699 0% |
| Other Solid Cancers | 1/94 1% | 5/1515 0% |
| Gastric Carcinoma | 3/74 4% | 3/1809 0% |
| Head and Neck Carcinoma | 2/85 2% | 3/1574 0% |
| Kidney Carcinoma | 1/85 1% | 4/1862 0% |
| Breast Carcinoma | 2/144 1% | 7/3264 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Hepatocellular Carcinoma | 3/46 7% | 2/2210 0% |
| Bladder Carcinoma | 0/58 0% | 2/956 0% |
| Glioma | 0/52 0% | 4/2127 0% |
Mutation Distribution
Where MICA is mutated · all tissues, split by cell line vs tissue
How many mutations in MICA were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 472 mutations in MICA
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|